论文部分内容阅读
目的探讨匹多莫得辅助治疗小儿呼吸道反复感染的临床疗效及其对患儿免疫功能的影响。方法选择广元市妇幼保健院2013年8月—2016年1月收治的呼吸道反复感染患儿150例,随机分为2组,每组75例,对照组患儿接受常规抗生素治疗,治疗组患儿在对照组治疗基础上加用匹多莫得治疗,持续治疗2个月,治疗结束后随访4个月,比较两组患儿治疗期间临床症状以及机体免疫功能的变化,同时比较随访期间两组患儿的临床疗效。结果治疗后,治疗组患儿咳嗽、发热、扁桃体发炎以及肺部哮鸣音消失的时间显著短于对照组(P<0.05)。治疗后,两组患儿血清免疫球蛋白水平较治疗前有所升高(P<0.05),其中治疗组患儿升高更为明显,与对照组比较具有统计学意义(P<0.05);治疗后两组患儿T细胞亚群CD3~+、CD4~+、CD8~+以及NK细胞相对活性都明显升高(P<0.05),且CD4~+/CD8~+相对含量同样升高(P<0.05),同时比较两组患儿治疗后各细胞水平,统计结果表明治疗组患儿改善情况更为明显(P<0.05)。治疗后,治疗组患儿治疗总有效率显著高于对照组(P<0.05),且治疗组患儿随访期间感染复发的次数显著少于对照组(P<0.05),且复发持续时间明显较短(P<0.05)。结论匹多莫得联合抗菌药物治疗小儿呼吸道反复感染效果显著,有效改善机体免疫功能,减少感染复发次数,值得临床推广应用。
Objective To investigate the clinical efficacy of pidotimod in adjuvant treatment of respiratory tract infections in children and its effect on immune function in children. Methods 150 cases of recurrent respiratory tract infection in Guangyuan MCH hospital from August 2013 to January 2016 were randomly divided into 2 groups (n = 75 in each group). The children in the control group received conventional antibiotics. The children in the treatment group On the basis of the control group, pidotimod was used to treat the patients for two months, and the patients were followed up for 4 months after the treatment. The clinical symptoms and immune function of the two groups were compared during the follow-up period. Clinical efficacy of children. Results After treatment, the duration of cough, fever, tonsil inflammation and lung wheezing disappeared in the treatment group was significantly shorter than that in the control group (P <0.05). After treatment, the serum immunoglobulin levels in both groups were significantly higher than those before treatment (P <0.05). The children in the treatment group increased more obviously than those in the control group (P <0.05). After treatment, the relative levels of CD3 ~ +, CD4 ~ +, CD8 ~ + and NK cells in the T cell subsets of the two groups were significantly increased (P <0.05) and the relative contents of CD4 ~ + / CD8 ~ P <0.05). At the same time, the levels of each cell in the two groups were compared. The statistical results showed that the improvement in the treatment group was more obvious (P <0.05). After treatment, the total effective rate of treatment group was significantly higher than that of control group (P <0.05), and the number of infection recurrence in treatment group was significantly less than that of control group (P <0.05), and the duration of recurrence was significantly Short (P <0.05). Conclusion Pidotime combined with antimicrobial drug treatment of children with recurrent respiratory tract infection has a significant effect, effectively improve the body’s immune function and reduce the number of infections relapsed, worthy of clinical application.